AXOL’s hiPSC-derived Microglia provide a reproducible, physiologically-relevant model in an easy-to-use, assay-ready format for investigating neuroglia involvement in neurodegeneration and neurodevelopment. This homogenous and reproducible population of iPSC-derived Microglia exhibit physiologically relevant functionality, are highly phagocytic and produce cytokines in response to pathogens. They also express the microglia-specific marker TMEM119 along with myeloid markers TREM2 and IBA-1, making these iPSC-derived Microglia suitable models for investigating neuroinflammation in Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.
CRF Bracket provides life science companies with patient-centric technology for clinical research including electronic clinical outcome assessments (eCOAs), eConsent, patient engagement, interactive response technology (IRT), clinical supply forecasting and management, and endpoint quality analytics and services. In 20 years the company has delivered solutions to over 4,000 global clinical trials.